Pharma Market Access Insights - from Petauri Evidence
Petauri Evidence
71 episodes
4 days ago
Send us a text What makes Switzerland a compelling first-launch market for Pharma? How does its healthcare system compare to other European countries? What do manufacturers need to know about reimbursement, pricing, and evidence requirements? How might the evolving Joint Clinical Assessment (JCA) landscape influence launch sequencing? This episode explores Switzerland’s potential as an early launch market. In this session, Louise Maddison (Senior Consultant – Global Pricing and Market Acces...
All content for Pharma Market Access Insights - from Petauri Evidence is the property of Petauri Evidence and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Send us a text What makes Switzerland a compelling first-launch market for Pharma? How does its healthcare system compare to other European countries? What do manufacturers need to know about reimbursement, pricing, and evidence requirements? How might the evolving Joint Clinical Assessment (JCA) landscape influence launch sequencing? This episode explores Switzerland’s potential as an early launch market. In this session, Louise Maddison (Senior Consultant – Global Pricing and Market Acces...
NHS policy for 2024/25: strategy and engagement in a world of uncertainty (recorded in Jan 2024)
Pharma Market Access Insights - from Petauri Evidence
1 hour 2 minutes
1 year ago
NHS policy for 2024/25: strategy and engagement in a world of uncertainty (recorded in Jan 2024)
What do we know about plans and policy for 2024/25? As the expected central operating plan had not materialised (at time of recording), and with a general election and a potential Labour government on the horizon, how can NHS and industry drive forward improvements and innovation?Host Robert Hull (Senior Consultant – NHS Insight & Interaction, Mtech Access) was joined by guest speakers Debbie Morgan (Director of Service Improvement and Transformation, Cambridge University Hospitals NHS Fo...
Pharma Market Access Insights - from Petauri Evidence
Send us a text What makes Switzerland a compelling first-launch market for Pharma? How does its healthcare system compare to other European countries? What do manufacturers need to know about reimbursement, pricing, and evidence requirements? How might the evolving Joint Clinical Assessment (JCA) landscape influence launch sequencing? This episode explores Switzerland’s potential as an early launch market. In this session, Louise Maddison (Senior Consultant – Global Pricing and Market Acces...
